Jefferies Financial Group lowered their Q1 2023 earnings estimates for shares of Pfizer in a note issued to investors on Friday, March 17th. Jefferies Financial Group analyst A. Tewari now anticipates that the biopharmaceutical company will post earnings per share of $0.72 for the quarter, down from their previous estimate of $0.78. Jefferies Financial Group has a “Hold” rating and a $43.00 price objective on the stock.